ClinVar Miner

Submissions for variant NM_058216.3(RAD51C):c.145+2_145+3insTT

dbSNP: rs1567783294
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV001011648 SCV001171994 uncertain significance Hereditary cancer-predisposing syndrome 2023-02-28 criteria provided, single submitter clinical testing The c.145+2_145+3insTT intronic variant, results from an insertion of two nucleotides (TT) between nucleotide position 145+2 and 145+3 after intron 1 of the RAD51C gene. In silico splice site analysis predicts that this alteration may weaken the native splice donor site. RNA studies have demonstrated that this alteration results in an incomplete splice defect; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Invitae RCV001037369 SCV001200779 uncertain significance Fanconi anemia complementation group O 2023-05-25 criteria provided, single submitter clinical testing In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 819250). This variant has not been reported in the literature in individuals affected with RAD51C-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change falls in intron 1 of the RAD51C gene. It does not directly change the encoded amino acid sequence of the RAD51C protein. It affects a nucleotide within the consensus splice site.
Color Diagnostics, LLC DBA Color Health RCV001011648 SCV001353937 uncertain significance Hereditary cancer-predisposing syndrome 2022-08-26 criteria provided, single submitter clinical testing This variant causes an insertion of two nucleotides in intron 1 splice donor site of the RAD51C gene. Splice site prediction tools predict that this variant may impact RNA splicing. This prediction has not been confirmed in published RNA studies. An external laboratory has reported that this variant does not result in significant abnormal splicing compared to non-carrier control samples (ClinVar Accession ID: SCV001171994.2). This variant has not been reported in individuals affected with hereditary cancer in the literature. This variant has been identified in 2/251282 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.